-
Company Profile
![]()
Disc Medicine Inc – Company Profile
Disc Medicine Inc (Disc Medicine), formerly Gemini Therapeutics Inc, is a biotechnology company, which develops first-in-class, disease-modifying precision medicines for dry age-related macular degeneration (AMD) and associated rare genetic diseases. The company product pipeline includes GEM103, a recombinant form of the human complement factor H protein that is designed to address complement hyperactivity and overall dysregulation and GEM307 to target complement factor H. The company works in partnership with research institutions and innovative companies including StrideBio Inc, Sanquin, Newcastle University,...
Add to Basket -
Product Insights
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome – Drugs In Development, 2022, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape. Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss...
-
Product Insights
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C – Drugs In Development, 2022, provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C (Genetic Disorders) pipeline landscape. Niemann-Pick C disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. It involves the accumulation of sphingolipids in cells throughout the body, particularly reticuloendothelial cells (the mononuclear phagocyte system). Symptoms include...
-
Product Insights
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...
-
Product Insights
Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, anxiety, loss of consciousness, and contraction or jerking of body muscles. The Epilepsy Drugs in Development market research report provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.